Rescue of mutant p53 transcription function by ellipticine

[1]  Jiandong Chen,et al.  Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization* , 2001, The Journal of Biological Chemistry.

[2]  R. Pochampally,et al.  Temperature-sensitive mutants of p53 homologs. , 2000, Biochemical and biophysical research communications.

[3]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[4]  Jiandong Chen,et al.  Activation of an MDM2-specific Caspase by p53 in the Absence of Apoptosis* , 1999, The Journal of Biological Chemistry.

[5]  P. Farnham,et al.  c-Myc target gene specificity is determined by a post-DNAbinding mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Lane,et al.  p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding , 1997, Oncogene.

[7]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[8]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[9]  W. Welch,et al.  Correcting temperature-sensitive protein folding defects. , 1997, The Journal of clinical investigation.

[10]  N. Osheroff,et al.  Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA. , 1995, The Journal of Biological Chemistry.

[11]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[12]  Chris Williams.  Oncology , 1990, The Lancet.

[13]  J. Droz,et al.  Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). , 1982, European journal of cancer & clinical oncology.

[14]  M. Saraste,et al.  FEBS Lett , 2000 .

[15]  G. Hortobagyi,et al.  Elliptinium acetate in metastatic breast cancer--a phase II study. , 1990, Oncology.